E!2328 GLIOPEP - Next generation Peptide Drug Conjugate as a novel tumour specific treatment for glioblastoma patients, Oncopeptides AB

Important results from the project

The project achieved all its objectives and established relevant glioblastoma models to evaluate novel peptide-drug conjugates. Results from the in vitro, ex vivo and in vivo studies exceeded expectations and provided a strong basis for continued development towards clinical studies. The project also strengthened collaboration between the partners and created new opportunities for joint studies and future projects.

Expected long term effects

The results support the continued clinical development of peptide-drug conjugates for hard-to-treat cancers. In the long term, the project is expected to contribute to new and improved treatment options for patients with glioblastoma, where the unmet need is substantial. The project also strengthens long-term collaborations and lays the foundation for new studies and innovations.

Approach and implementation

The project was implemented as planned through complementary in vitro, ex vivo and in vivo studies, with each partner having a clearly defined role. The activities were well chosen, and the project progressed as intended, with results exceeding expectations. The timeline was largely maintained, and no major external or unforeseen factors affected implementation. Collaboration worked very well, supported by effective communication, engagement and constructive discussions.